- Home
- NEU vs VCEL Comparison
NEU vs VCEL Comparison
Compare NEU & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEU
- VCEL
- Stock Information
- Founded
- NEU 1887
- VCEL 1989
- Country
- NEU United States
- VCEL United States
- Employees
- NEU N/A
- VCEL N/A
- Industry
- NEU Major Chemicals
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEU Industrials
- VCEL Health Care
- Exchange
- NEU Nasdaq
- VCEL Nasdaq
- Market Cap
- NEU N/A
- VCEL 2.8B
- IPO Year
- NEU N/A
- VCEL 1997
- Fundamental
- Price
- NEU $506.82
- VCEL $57.50
- Analyst Decision
- NEU
- VCEL Strong Buy
- Analyst Count
- NEU 0
- VCEL 6
- Target Price
- NEU N/A
- VCEL $61.83
- AVG Volume (30 Days)
- NEU 41.3K
- VCEL 332.4K
- Earning Date
- NEU 01-29-2025
- VCEL 02-27-2025
- Dividend Yield
- NEU 1.97%
- VCEL N/A
- EPS Growth
- NEU 9.11
- VCEL N/A
- EPS
- NEU 45.05
- VCEL 0.07
- Revenue
- NEU $2,775,261,000.00
- VCEL $226,844,000.00
- Revenue This Year
- NEU N/A
- VCEL $23.82
- Revenue Next Year
- NEU N/A
- VCEL $22.51
- P/E Ratio
- NEU $11.25
- VCEL $799.92
- Revenue Growth
- NEU 1.37
- VCEL 22.48
- 52 Week Low
- NEU $494.04
- VCEL $32.31
- 52 Week High
- NEU $650.00
- VCEL $61.49
- Technical
- Relative Strength Index (RSI)
- NEU 30.54
- VCEL 57.07
- Support Level
- NEU $520.10
- VCEL $54.41
- Resistance Level
- NEU $537.20
- VCEL $58.00
- Average True Range (ATR)
- NEU 11.80
- VCEL 2.31
- MACD
- NEU -2.25
- VCEL -0.34
- Stochastic Oscillator
- NEU 3.54
- VCEL 62.83
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.